Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cardiol Therapeutics Inc. (CRDL) had Return on Tangible Equity of -67.66% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-8.29M |
|
-- |
|
-- |
|
$8.43M |
|
$-8.43M |
|
$0.14M |
|
$-8.29M |
|
$-8.29M |
|
$-8.29M |
|
$-8.29M |
|
$-8.29M |
|
$-8.29M |
|
$-8.43M |
|
$-8.41M |
|
82.61M |
|
82.61M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$17.60M |
|
$0.13M |
|
$0.13M |
|
$17.73M |
|
$5.40M |
|
$0.08M |
|
$0.08M |
|
$5.48M |
|
$12.25M |
|
$12.25M |
|
$12.25M |
|
82.61M |
|
| Cash Flow Statement Financials | |
$-4.98M |
|
$-0.01M |
|
$-0.01M |
|
$21.30M |
|
$16.22M |
|
$-5.07M |
|
$0.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.26 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-67.66% |
|
|
Return on Tangible Equity |
-67.66% |
-46.75% |
|
-67.22% |
|
$0.15 |
|
$-0.06 |
|
$-0.06 |
|